SPHK1 overexpression helps AML cells resist sorafenib by enhancing β-catenin levels (46), suggesting that targeting the SPHK1/S1P axis and β-catenin could mitigate sorafenib resistance. This evidence concerns the gene SPHK1 and acute myeloid leukemia.